Molecular characterization of extrahepatic cholangiocarcinoma: perihilar and distal tumors display divergent genomic and transcriptomic profiles

References

• Castro FA, Koshiol J, Hsing AW, et al. Biliary tract cancer incidence in the United States-Demographic and temporal variations by anatomic site. Int J Cancer. 2013;133(7):1664–1671.
   PubMed Web of Science ®Google Scholar
• WHO Editorial Board Members. WHO classification – tumours of the digestive system. 5th ed. Lyon: IARC Press; 2019.
   Google Scholar
• Minicozzi P, Cassetti T, Vener C, et al. Analysis of incidence, mortality and survival for pancreatic and biliary tract cancers across Europe, with assessment of influence of revised European age standardisation on estimates. Cancer Epidemiol. 2018;55:52–60.
   PubMed Web of Science ®Google Scholar
• Ercolani G, Dazzi A, Giovinazzo F, et al. Intrahepatic, peri-hilar and distal cholangiocarcinoma: three different locations of the same tumor or three different tumors? Eur J Surg Oncol. 2015;41(9):1162–1169.
   PubMed Web of Science ®Google Scholar
• Tantau AI, Mandrutiu A, Pop A, et al. Extrahepatic cholangiocarcinoma: current status of endoscopic approach and additional therapies. World J Hepatol. 2021;13(2):166–186.
   PubMed Web of Science ®Google Scholar
• Ren B, Guo Q, Yang Y, et al. A meta-analysis of the efficacy of postoperative adjuvant radiotherapy versus no radiotherapy for extrahepatic cholangiocarcinoma and gallbladder carcinoma. Radiat Oncol. 2020;15(1):15.
   PubMed Web of Science ®Google Scholar
• Ghouri YA, Mian I, Blechacz B. Cancer review: cholangiocarcinoma. J Carcinog. 2015;14:1.
   PubMedGoogle Scholar
• Nooijen LE, Swijnenburg RJ, Klümpen HJ, et al. Surgical therapy for perihilar cholangiocarcinoma: state of the Art. Visc Med. 2021;37:18–25.
   PubMed Web of Science ®Google Scholar
• Kam AE, Masood A, Shroff RT. Current and emerging therapies for advanced biliary tract cancers. Lancet Gastroenterol Hepatol. 2021;6(11):956–969.
   PubMed Web of Science ®Google Scholar
• Amini A, Gamblin TC. Palliation: treating patients with inoperable biliary tract and primary liver tumors. Surg Oncol Clin N Am. 2014;23(2):383–397.
   PubMed Web of Science ®Google Scholar
• Okusaka T, Ojima H, Morizane C, et al. Emerging drugs for biliary cancer. Expert Opin Emerg Drugs. 2014;19(1):11–24.
   PubMed Web of Science ®Google Scholar
• Simbolo M, Fassan M, Ruzzenente A, et al. Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups. Oncotarget. 2014;5(9):2839–2852.
   PubMedGoogle Scholar
• Jiao Y, Pawlik TM, Anders RA, et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet. 2013;45(12):1470–1473.
   PubMed Web of Science ®Google Scholar
• Nakamura H, Arai Y, Totoki Y, et al. Genomic spectra of biliary tract cancer. Nat Genet. 2015;47(9):1003–1010.
   PubMed Web of Science ®Google Scholar
• Chan-On W, Nairismagi ML, Ong CK, et al. Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat Genet. 2013;45:1474–1478.
   PubMed Web of Science ®Google Scholar
• Churi CR, Shroff R, Wang Y, et al. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS One. 2014;9(12):e115383.
   PubMed Web of Science ®Google Scholar
• Miller G, Socci ND, Dhall D, et al. Genome wide analysis and clinical correlation of chromosomal and transcriptional mutations in cancers of the biliary tract. J Exp Clin Cancer Res. 2009;28(1):62.
   PubMedGoogle Scholar
• Simbolo M, Vicentini C, Ruzzenente A, et al. Genetic alterations analysis in prognostic stratified groups identified TP53 and ARID1A as poor clinical performance markers in intrahepatic cholangiocarcinoma. Sci Rep. 2018;8(1):7119.
   PubMedGoogle Scholar
• Jusakul A, Cutcutache I, Yong CH, et al. Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma. Cancer Discov. 2017;7(10):1116–1135.
   PubMed Web of Science ®Google Scholar
• Lee H, Wang K, Johnson A, et al. Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets. J Clin Pathol. 2016;69(5):403–408.
   PubMed Web of Science ®Google Scholar
• Ruzzenente A, Fassan M, Conci S, et al. Cholangiocarcinoma heterogeneity revealed by multigene mutational profiling: clinical and prognostic relevance in surgically resected patients. Ann Surg Oncol. 2016;23(5):1699–1707.
   PubMed Web of Science ®Google Scholar
• Wardell CP, Fujita M, Yamada T, et al. Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations. J Hepatol. 2018;68(5):959–969.
   PubMed Web of Science ®Google Scholar
• Peck J, Wei L, Zalupski M, et al. HER2/neu may not be an interesting target in biliary cancers: results of an early phase II study with lapatinib. Oncology. 2012;82(3):175–179.
   PubMed Web of Science ®Google Scholar
• Jensen LH, Lindebjerg J, Ploen J, et al. Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer. Ann Oncol. 2012;23(9):2341–2346.
   PubMed Web of Science ®Google Scholar
• Lee J, Park SH, Chang HM, et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2012;13:181–188.
   PubMed Web of Science ®Google Scholar
• Malka D, Cervera P, Foulon S, et al. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. Lancet Oncol. 2014;15(8):819–828.
   PubMed Web of Science ®Google Scholar
• Lubner SJ, Mahoney MR, Kolesar JL, et al. Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study. J Clin Oncol. 2010;28(21):3491–3497.
   PubMed Web of Science ®Google Scholar
• Cadamuro M, Lasagni A, Lamarca A, et al. Targeted therapies for extrahepatic cholangiocarcinoma: preclinical and clinical development and prospects for the clinic. Expert Opin Investig Drugs. 2021;30(4):377–388.
   PubMed Web of Science ®Google Scholar
• Amin MB, Edge SB, Greene FL, et al. AJCC cancer staging manual. 8th. Chicago: Springer; 2017.
   Google Scholar
• Simbolo M, Gottardi M, Corbo V, et al. DNA qualification workflow for next generation sequencing of histopathological samples. PLoS One. 2013;8(6):e62692.
   PubMed Web of Science ®Google Scholar
• Zamo A, Bertolaso A, van Raaij AW, et al. Application of microfluidic technology to the BIOMED-2 protocol for detection of B-cell clonality. J Mol Diagn. 2012;14:30–37.
   PubMed Web of Science ®Google Scholar
• Corbo V, Beghelli S, Bersani S, et al. Pancreatic endocrine tumours: mutational and immunohistochemical survey of protein kinases reveals alterations in targetable kinases in cancer cell lines and rare primaries. Ann Oncol. 2012;23(1):127–134.
   PubMed Web of Science ®Google Scholar
• Brunelli M, Manfrin E, Martignoni G, et al. Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: evaluation according to ASCO/CAP criteria. Am J Clin Pathol. 2009;131:678–682.
   PubMed Web of Science ®Google Scholar
• Xu Z, Dai J, Wang D, et al. Assessment of tumor mutation burden calculation from gene panel sequencing data. Onco Targets Ther. 2019;12:3401–3409.
   PubMed Web of Science ®Google Scholar
• Campbell BB, Light N, Fabrizio D, et al. Comprehensive analysis of hypermutation in human cancer. Cell. 2017;171:1042–1056.e10.
   PubMed Web of Science ®Google Scholar
• Muggeo VM. Estimating regression models with unknown break-points. Stat Med. 2003;22:3055–3071.
   PubMed Web of Science ®Google Scholar
• Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545–15550.
   PubMed Web of Science ®Google Scholar
• Liberzon A, Subramanian A, Pinchback R, et al. Molecular signatures database (MSigDB) 3.0. Bioinformatics. 2011;27(12):1739–1740.
   PubMed Web of Science ®Google Scholar
• Montal R, Sia D, Montironi C, et al. Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma. J Hepatol. 2020;73(2):315–327.
   PubMed Web of Science ®Google Scholar
• Sia D, Hoshida Y, Villanueva A, et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology. 2013;144(4):829–840.
   PubMed Web of Science ®Google Scholar
• Luo W, Friedman MS, Shedden K, et al. GAGE: generally applicable gene set enrichment for pathway analysis. BMC Bioinformatics. 2009;10(1):161.
   PubMedGoogle Scholar
• Li T, Fu J, Zeng Z, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48(W1):W509–W514.
   PubMed Web of Science ®Google Scholar
• Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 2017;18(1):220.
   PubMed Web of Science ®Google Scholar
• Sabbatino F, Villani V, Yearley JH, et al. PD-L1 and HLA class i antigen expression and clinical course of the disease in intrahepatic cholangiocarcinoma. Clin Cancer Res. 2016;22(2):470–478.
   PubMed Web of Science ®Google Scholar
• Luchini C, Cros J, Pea A, et al. PD-1, PD-L1, and CD163 in pancreatic undifferentiated carcinoma with osteoclast-like giant cells: expression patterns and clinical implications. Hum Pathol. 2018;81:157–165.
   PubMed Web of Science ®Google Scholar
• Luchini C, Bibeau F, Ligtenberg MJL, et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann Oncol. 2019;30(8):1232–1243.
   PubMed Web of Science ®Google Scholar
• Yachida S, Wood LD, Suzuki M, et al. Genomic sequencing identifies ELF3 as a driver of ampullary carcinoma. Cancer Cell. 2016;29(2):229–240.
   PubMed Web of Science ®Google Scholar
• Barresi V, Simbolo M, Mafficini A, et al. Ultra-Mutation in IDH Wild-Type Glioblastomas of Patients Younger than 55 Years is Associated with Defective Mismatch Repair, Microsatellite Instability, and Giant Cell Enrichment. Cancers (Basel). 2019;11:1279.
   Web of Science ®Google Scholar
• Simbolo M, Mafficini A, Sikora KO, et al. Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D. J Pathol. 2017;241:488–500.
   PubMed Web of Science ®Google Scholar
• Lawlor RT, Mattiolo P, Mafficini A, et al. Tumor mutational burden as a potential biomarker for immunotherapy in pancreatic cancer: systematic review and still-open questions. Cancers (Basel). 2021;13(13):3119.
   PubMed Web of Science ®Google Scholar
• Luchini C, Brosens LAA, Wood LD, et al. Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications. Gut. 2021;70:148–156.
   PubMed Web of Science ®Google Scholar
• Kamal Y, Dwan D, Hoehn HJ, et al. Tumor immune infiltration estimated from gene expression profiles predicts colorectal cancer relapse. Oncoimmunology. 2021;10(1):1862529.
   PubMed Web of Science ®Google Scholar
• Dallavalasa S, Beeraka NM, Basavaraju CG, et al. The role of Tumor Associated Macrophages (TAMs) in cancer progression, chemoresistance, angiogenesis and metastasis - current status. Curr Med Chem. 2021; Epub ahead of print. DOI:https://doi.org/10.2174/0929867328666210720143721.
   Google Scholar
• Jamiyan T, Kuroda H, Yamaguchi R, et al. CD68- and CD163-positive tumor-associated macrophages in triple negative cancer of the breast. Virchows Arch. 2020;477(6):767–775.
   PubMed Web of Science ®Google Scholar
• Duan Q, Zhang H, Zheng J, et al. Turning cold into hot: firing up the tumor microenvironment. Trends Cancer. 2020;6:605–618.
   PubMed Web of Science ®Google Scholar
• Bagante F, Spolverato G, Ruzzenente A, et al. Artificial neural networks for multi-omics classifications of hepato-pancreato-biliary cancers: towards the clinical application of genetic data. Eur J Cancer. 2021;148:348–358.
   PubMed Web of Science ®Google Scholar